Infinity Regains Pipeline Rights, Gives Up Equity In Rejiggered Purdue Alliance

Infinity avoids the erosion of its rights to a promising PI3K drug by restructuring its alliance with Purdue and Mundipharma, essentially returning all control back to the cancer drug developer.